Literature DB >> 31187576

Bundling mRNA Strands to Prepare Nano-Assemblies with Enhanced Stability Towards RNase for In Vivo Delivery.

Naoto Yoshinaga1, Eol Cho1, Kyoko Koji1, Yuki Mochida2, Mitsuru Naito3, Kensuke Osada4, Kazunori Kataoka2,5, Horacio Cabral1, Satoshi Uchida1,2.   

Abstract

Ribonuclease (RNase)-mediated degradation of messenger RNA (mRNA) poses a huge obstruction to in vivo mRNA delivery. Herein, we propose a novel strategy to protect mRNA by structuring mRNA to prevent RNase attack through steric hinderance. Bundling of mRNA strands through hybridization of RNA oligonucleotide linkers allowed the preparation of mRNA nano-assemblies (R-NAs) comprised of 7.7 mRNA strands on average, mostly below 100 nm in diameter. R-NA formation boosted RNase stability by around 100-fold compared to naïve mRNA and preserved translational activity, allowing protein production. A mechanistic analysis suggests that an endogenous mRNA unwinding mechanism triggered by 5'-cap-dependent translation may induce selective R-NA dissociation intracellularly, leading to smooth translation. R-NAs showed efficient mRNA transfection in mouse brain, demonstrating the feasibility for in vivo administration.
© 2019 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  RNA structure; drug delivery; gene technology; mRNA; ribonuclease

Mesh:

Substances:

Year:  2019        PMID: 31187576     DOI: 10.1002/anie.201905203

Source DB:  PubMed          Journal:  Angew Chem Int Ed Engl        ISSN: 1433-7851            Impact factor:   15.336


  10 in total

Review 1.  mRNA-based therapeutics: powerful and versatile tools to combat diseases.

Authors:  Shugang Qin; Xiaoshan Tang; Yuting Chen; Kepan Chen; Na Fan; Wen Xiao; Qian Zheng; Guohong Li; Yuqing Teng; Min Wu; Xiangrong Song
Journal:  Signal Transduct Target Ther       Date:  2022-05-21

2.  Isolation and characterization of microvesicles from mesenchymal stem cells.

Authors:  M Rezaa Mohammadi; Milad Riazifar; Egest J Pone; Ashish Yeri; Kendall Van Keuren-Jensen; Cecilia Lässer; Jan Lotvall; Weian Zhao
Journal:  Methods       Date:  2019-10-25       Impact factor: 3.608

Review 3.  Strategies to deliver RNA by nanoparticles for therapeutic potential.

Authors:  Alysia Cox; Siyoung A Lim; Eun Ji Chung
Journal:  Mol Aspects Med       Date:  2021-08-05

Review 4.  In vivo gene delivery mediated by non-viral vectors for cancer therapy.

Authors:  Reza Mohammadinejad; Ali Dehshahri; Vijay Sagar Madamsetty; Masoumeh Zahmatkeshan; Shima Tavakol; Pooyan Makvandi; Danial Khorsandi; Abbas Pardakhty; Milad Ashrafizadeh; Elham Ghasemipour Afshar; Ali Zarrabi
Journal:  J Control Release       Date:  2020-07-04       Impact factor: 9.776

5.  mRNA as a Tool for Gene Transfection in 3D Cell Culture for Future Regenerative Therapy.

Authors:  Satoshi Uchida; Kayoko Yanagihara; Akitsugu Matsui; Kazunori Kataoka; Keiji Itaka
Journal:  Micromachines (Basel)       Date:  2020-04-18       Impact factor: 2.891

Review 6.  Nanomaterial Delivery Systems for mRNA Vaccines.

Authors:  Michael D Buschmann; Manuel J Carrasco; Suman Alishetty; Mikell Paige; Mohamad Gabriel Alameh; Drew Weissman
Journal:  Vaccines (Basel)       Date:  2021-01-19

Review 7.  Clinical progress of nanomedicine-based RNA therapies.

Authors:  Siyoung A Lim; Alysia Cox; Madelynn Tung; Eun Ji Chung
Journal:  Bioact Mater       Date:  2021-10-22

8.  Delivery Systems of Plasmid DNA and Messenger RNA for Advanced Therapies.

Authors:  Satoshi Uchida
Journal:  Pharmaceutics       Date:  2022-04-07       Impact factor: 6.525

Review 9.  Multifunctional Immunoadjuvants for Use in Minimalist Nucleic Acid Vaccines.

Authors:  Saed Abbasi; Satoshi Uchida
Journal:  Pharmaceutics       Date:  2021-05-01       Impact factor: 6.321

10.  PEGylation of mRNA by Hybridization of Complementary PEG-RNA Oligonucleotides Stabilizes mRNA without Using Cationic Materials.

Authors:  Naoto Yoshinaga; Mitsuru Naito; Yoshihiro Tachihara; Eger Boonstra; Kensuke Osada; Horacio Cabral; Satoshi Uchida
Journal:  Pharmaceutics       Date:  2021-05-27       Impact factor: 6.321

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.